Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DQX83Z
|
|||
| Drug Name |
INCB81776
|
|||
| Synonyms |
INCB081776
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199] | Phase 1 | [1] | |
| Company |
Incyte
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Tyrosine-protein kinase Mer (MERTK) | Target Info | Inhibitor | [2] |
| Tyrosine-protein kinase UFO (AXL) | Target Info | Inhibitor | [2] | |
| NetPath Pathway | TSH Signaling Pathway | |||
| FSH Signaling Pathway | ||||
| Pathway Interaction Database | Validated transcriptional targets of deltaNp63 isoforms | |||
| Reactome | Cell surface interactions at the vascular wall | |||
| VEGFA-VEGFR2 Pathway | ||||
| WikiPathways | Cell surface interactions at the vascular wall | |||
| miR-targeted genes in squamous cell - TarBase | ||||
| miR-targeted genes in muscle cell - TarBase | ||||
| miR-targeted genes in lymphocytes - TarBase | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03522142) A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies. U.S. National Institutes of Health. | |||
| REF 2 | A Potent and Selective Dual Inhibitor of AXL and MERTK Possesses Both Immunomodulatory and Tumor-Targeted Activity. Front Oncol. 2020 Dec 7;10:598477. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.